麻豆传媒

Dr. Timothy M. Kuzel, a leading authority on developing innovative immunotherapy treatments for cancer, is the Rush University Medical division chief of Hematology, Oncology and Cell Therapy and professor of internal medicine
Kuzel is a past winner of the

Dr. Preston C. Sprenkle specializes in the treatment of urologic cancers, including prostate cancer, kidney cancer, bladder cancer, testicular cancer and sarcoma 鈥� a rare kind of cancer that grows in cells that connect or support other parts of the body, like bone or muscle.
Dr. Sprenkle has dedicated his career to using the latest imaging technologies to improve diagnosis. He was one of the first physicians nationwide to implement the use of the Artemis Device. This machine, introduced in 2009, allows a surgeon to use 3D ultrasound technology and merge it with even more precise magnetic resonance imaging (MRI) to accurately identify cancerous tumors.
鈥淪killed and experienced radiologists are rare for this relatively new technique,鈥� Dr. Sprenkle explains. 鈥淎t Yale, we are fortunate to have some of the world leaders in prostate MRI.鈥�
Dr. Sprenkle is also a pioneer in 鈥渇ocal therapy,鈥� which allows a surgeon to treat tiny prostate lesions, rather than the whole organ. This avoids many of the side effects鈥攕uch as erectile dysfunction and incontinence鈥攖hat may follow the removal of the whole prostate.
鈥淓xciting technological advances are revolutionizing urology. Prostate cancer is very common and current treatments can majorly impact a man's sexual and urinary function,鈥� Dr. Sprenkle says. 鈥淒eveloping ways to minimize the impact of prostate cancer diagnosis and treatment on a man's health and quality of life is tremendously rewarding.鈥�
Dr. Sprenkle believes in working with patients to come up with individualized treatment plans. 鈥淚 want my patients to feel that I hear their concerns and treat them like a person. I am pleased at the end of a long consultation when they feel like they understand their disease and their options.鈥�

Education & Training:
Non Degree Program-Yale School of Management, Emerging Leaders Program (2018)
Fellowship-Memorial Sloan Kettering Cancer Center (2011)
Residency-New York Presbyterian Hospital (2009)
Internship-New York Presbyterian Hospital (2005)
MD-Columbia University (2004)
BA-Stanford University, Human Biology (1998)

David Braun, MD, PhD, is an Assistant Professor of Medicine (Medical Oncology) and a member of the Center of Molecular and Cellular Oncology (CMCO) at Yale Cancer Center. Dr. Braun cares for patients with kidney cancers. He received his PhD in Computational Biology from the Courant Institute of Mathematical Science at New York University and his medical degree from Icahn School of Medicine at Mount Sinai. He completed his residency at the Brigham and Women’s Hospital where he received the Dunn Medical Intern Award and served as Chief Medical Resident before completing fellowship training in adult oncology through the Dana-Farber/Partners CancerCare program where he was appointed the Emil Frei Fellow and the John R. Svenson Fellow.
Dr. Braun joined Yale from Dana-Farber Cancer Institute where he was an Instructor in Medicine with clinical and scientific interest in understanding and improving immune therapies for kidney cancer. He has a longstanding interest in integrating experimental and computational approaches to biomedical research and is currently studying mechanisms of response and resistance to immune therapy in kidney cancer, with the goal of developing novel therapies. He continues this work as part of the CMCO, which fosters and mentors physician-scientists as they advance their laboratory-based research programs to bridge fundamental cancer biology with clinical investigation for the translation of basic discoveries into better treatments or diagnosis.

Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Medical Director, International Strategic Initiatives at Dana-Farber and past President of the Medical Staff at DFCI (2016-2018). He received the George Canellos Award for Excellence in Clinical Investigation and Patient Care from DFCI in 2013, the Eugene Schonfeld Award from the Kidney Cancer Association (KCA) in 2016, and is a 2021 Giants of Cancer Care inductee. He serves on the National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel, KidneyCan Board, the National Cancer Institute (NCI) GU Steering Committee, and is past Chairman (2015-2018) of the Medical and Scientific Steering Committee of the KCA. Dr. Choueiri is an elected member of the American Society of Clinical Investigation (ASCI). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania.
Dr. Choueiri is interested in developing novel experimental therapies and biomarkers in GU malignancies, including renal cell carcinoma (RCC). In a series of New England Journal of Medicine (NEJM) articles on which he was either first or senior author, Dr. Choueiri and colleagues have made seminal observations that have defined and evolved the treatment of metastatic RCC and led to the approval of several therapies such as Cabozantinib, Pazopanib, Avelumab+Axitinib, Cabozantinib+Nivolumab, and Pembrolizumab+Lenvatinib, as well as adjuvant pembrolizumab. His research also focuses on the epidemiology, diagnosis, and treatment outcomes of GU cancers, especially through having co-established the International Metastatic RCC Database Consortium criteria for RCC risk stratification. His biomarker work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy. He has also contributed to our understanding of the underlying biology and rationale for therapies in rare histological variants of RCC such as papillary, translocation, and sarcomatoid RCC.
Dr. Choueiri has received research funding from the NCI, the Department of Defense (DOD), the American Society of Clinical Oncology (ASCO), and industry partners. His work has been published in journals such as the NEJM, Nature, Nature Medicine, Science, Cancer Cell, Journal of American Medical Association (JAMA), JAMA Oncology, The Lancet, Lancet Oncology, and Journal of Clinical Oncology. He lectures frequently throughout the United States and around the world. He has over 675 PubMed-indexed publications and is the lead investigator of multiple national and international phase I-III trials in GU cancers.

Dr. Marron received his medical degree from the David Geffen School of Medicine at UCLA in 2008. He completed his residency in Pediatrics at Stanford University and his fellowship in Clinical Medical Ethics at the University of Chicago followed by his fellowship in Pediatric Hematology/Oncology at Boston Children's Hospital and the Dana-Farber Cancer Institute. Dr. Marron also received an MPH in 2016 from the Harvard T.H. Chan School of Public Health. Jonathan cares for pediatric oncology patients in the inpatient setting at Boston Children's Hospital and in the outpatient clinic at the Dana-Farber Cancer Institute. His research interests are in ethics and decision-making, health services, clinical genomics, informed consent, and medical uncertainty. Much of Dr. Marron's current work focuses on patient, parent and physician decision-making regarding pediatric precision cancer medicine. He also teaches medical ethics to medical students and graduate students through his role as teaching faculty at the Harvard Medical School Center for Bioethics.

Marc Matrana, MD, is a medical oncologist at Ochsner MD Anderson Cancer Center in New Orleans. He serves as chief of precision medicine for Ochsner Health. He is a nationally recognized expert on kidney cancer and frequently serves as a presenter at medical conferences on the subject. His research in the field has appeared numerous times in peer-reviewed publications. His expertise includes personalized medicine and genomics, including multi-cancer early detection tests and pharmacogenomics.

Dr. Matrana focuses on cancers of the genitourinary tract, which includes the kidneys, bladder and urethra, as well as reproductive organs. 
A New Orleans native, he earned a medical degree from the Louisiana State University Health Sciences Center New Orleans. He completed an internship and residency in internal medicine at Ochsner Medical Center. He completed a fellowship in hematology and medical oncology at MD Anderson Cancer Center in Houston.